Cite
MLA Citation
Z Liu et al.. “OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study.” Journal of Crohn's and colitis, vol. 17, n.d., pp. i32–i34. http://access.bl.uk/ark:/81055/vdc_100179844346.0x00001c